Some Breast Cancers Fail to Respond to Treatments, Why?

Breast Cancer

Most breast cancers are estrogen receptor-positive, meaning that signals received from estrogen, a hormone, promote the growth of the tumors. To stop these cancers from spreading, estrogen inhibitors are usually prescribed. But what happens when tumors develop treatment resistance?

Studies suggest that "approximately 70 percent" of all the breast cancers are estrogen receptor-positive (ER-positive).

These types of cancer are typically treated with drugs — such as tamoxifen and fulvestrant — that either lower the levels of the hormone or inhibit the estrogen receptors to prevent the tumors from spreading. This is known as endocrine therapy.

However, around a third of the people treated with these drugs develop resistance to them, which negatively impacts their chances of survival. The mechanisms that underlie the tumors' resistance to therapy is not well understood and currently poses a major challenge.

Read More »

Breast Cancer: The Body of Knowledge Grows

Scientists’ understanding of the genetics/genomics of breast cancer continues to grow; a revolution is underway both in terms of categorizing breast cancers and targeting treatment that will be effective in individual cases. New perspectives are being offered on the interpretation of biopsies, too. Here is a round-up of some very recent studies.

Genetic variants alter cells’ response to estrogen

An international study of almost 120,000 women has newly identified five genetic variants affecting risk of breast cancer, all of which are believed to influence how breast cells respond to the female sex hormone estrogen.

Estrogen acts as a trigger, binding to a molecule known as an estrogen receptor in most breast cells and triggering a cascade of signals that cause the cell to behave normally. However, the estrogen receptor is switched off in some cells and these do not respond to the hormone.

Read more: Breast Cancer: The Body of Knowledge Grows

Source: MedicalLaboratoryObserver

What Does Breast Cancer Feel Like? Lumps and Pain Explained

In breast cancer, abnormal genes cause breast cells to grow uncontrollably and not die off as they normally would.

If these cells grow slowly and don't invade other tissues, they cause benign tumors. These are lumps that are not usually considered dangerous to health.

When abnormal cells grow at a more rapid rate and begin to invade surrounding tissues, they form cancerous tumors. These lumps pose a serious risk and can spread, creating new tumors throughout the body.

Read more: What Does Breast Cancer Feel Like? Lumps and Pain Explained

When breast cancer first appears, it can cause a wide range of different symptoms. Always seek
medical attention if in doubt about possible breast symptoms. Breast cancer can also affect men.

Source: MedicalNewsToday

Early Signs That Cancer Is Growing In Your Body

There’s an important rule about cancer, one of the leading causes of death in the world, and it’s the sooner it’s detected, the higher chances of successful treatment.

Because of that fact, don’t rely on routine tests alone to protect you from cancer. It’s just as important to listen to your body and notice anything that’s different, odd, or unexplainable.

Here are some early signs that are commonly overlooked:

1.Wheezing or shortness of breath

One of the first signs many lung cancer patients remember noticing is the inability to catch their breath.

2.Chronic cough or chest pain

Several types of cancer, including leukemia and lung tumors, can cause symptoms that mimic a bad cough or bronchitis. Some lung cancer patients report chest pain that extends up into the shoulder or down the arm.

Read more: Early Signs That Cancer Is Growing In Your Body

Source: healthiestalternative

Know the Common Causes of Breast Pain

Women of all ages report having breast pain, also known as mastalgia. Pain can occur both before and after the menopause. However, breast pain is most common in younger menstruating women.

While nearly 70 percent of women report breast pain at some point during their lives, only around 15 percent require medical treatment.

The severity and location of breast pain can vary. Pain can occur in both breasts, one breast, or in the underarm. Severity can range from mild to severe and is typically described as tenderness, sharp burning, or tightening of the breast tissue.

Hormonal changes due to events such as menstruation, pregnancy, lactation, and menopause can also have an effect on the type of breast pain experienced.

Read more: Common Causes of Breast Pain

Breast pain can sometimes occur alongside changes in the menstrual cycle. Oral hormonal contraceptives
can lead to breast pain in some cases.

Source: medicalnewstoday

New 'Mutation-Tracking' Blood Test Could Predict Breast Cancer Relapse Months in Advance

Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.

The test can uncover small numbers of residual cancer cells that have resisted therapy by detecting cancer DNA in the bloodstream.

Researchers at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust were able to track key mutations that cancer accumulates as it develops and spreads, without the need for invasive biopsy procedures.

They hope that by deciphering the DNA code found in blood samples, it should be possible to identify the particularly mutations likely to prove lethal to that patient - and tailor treatment accordingly.

Read more: New 'Mutation-Tracking' Blood Test Could Predict Breast Cancer Relapse Months in Advance

Source: medicalxpress

Gene Mutation 'Hotspots' Linked to Better Cancer Outcomes

Patients with the mutations tended to survive longer and had tumors more susceptible to aggressive treatment.

Breast cancer patients with groups of mutations clustered in their genome have better outcomes than patients without them, researchers found in a recent study.

More than half of breast cancer patients have clusters of genetic mutations called kataegis, and their cancer tends to be less invasive, offering better opportunities for effective treatment, according to researchers at the University of California San Diego.

Read more: Gene Mutation 'Hotspots' Linked to Better Cancer Outcomes

Although researchers are unsure of how the clusters of genetic mutations called kataegis occur,
but cancer patients who have them in tumors tend to respond better to treatment and have better
outcomes, according to a recent study.

Source: cigdem/Shutterstock

Cancer Breakthrough? Novel Insight into Metastasis Could Offer New Treatments

Researchers from the United Kingdom may have made a breakthrough in cancer treatment, after discovering an unusual mechanism by which cancer cells spread and survive in the body.

In a study published in Nature Communications, researchers reveal how two molecules join forces to help cancer cells survive as they metastasize.

Metastasis is the process by which cancer cells break away from the primary tumor and spread to other parts of the body through the bloodstream or lymph system.

Once cancer has spread, the disease becomes much more challenging to treat Chemotherapy, hormone therapy, radiotherapy, and other treatments can yield success for some metastatic cancers, but for most, the prognosis is poor.

Read more: Cancer Breakthrough? Novel Insight into Metastasis Could Offer New Treatments

Source: medicalnewstoday

Breast Cancer Treatment Breakthrough After 'Milestone' Genetic Discovery

The latest breast cancer research could lead to more personalized care for patients and help further understanding of the causes of the disease, scientists said.

A study involving people from around the world has been hailed as giving a more complete picture of the changes in DNA in breast cancer, providing potential opportunities for new treatments.

A study of 560 breast cancer genomes, or complete genetic codes, turned up five new genes associated with the disease.

Read more: Breast Cancer Treatment Breakthrough After 'Milestone' Genetic Discovery

Source: IndependentPrintLimited

Breast Cancer: Existing Drug Shows Promise for Prevention in High-Risk Women

Researchers have identified an existing drug that they say has the potential to prevent or delay breast cancer for women at high risk of developing the disease.

In a study published the journal Nature Medicine, researchers reveal how the drug denosumab halted the growth of pre-cancerous cells in breast tissue of women with a faulty BRCA1 gene.

Women with a BRCA1 gene mutation are at significantly greater risk for breast and ovarian cancers; around 55-65 percent of women with such a mutation will develop the disease by the age of 70, according to the National Cancer Institute, compared with 12 percent of those in the general population.

Read more:  Breast Cancer: Existing Drug Shows Promise for Prevention in High-Risk Women

Researchers found the drug denosumab stopped the growth of cells that are a precursor to breast cancer
in women with a BRCA1 gene mutation.

Source: medicalnewstoday

New gene testing method can identify mutations, prioritize variants in breast and ovarian cancer genes

A research team led by an award-winning genomicist at Western University has developed a new method for identifying mutations and prioritizing variants in breast and ovarian cancer genes, which will not only reduce the number of possible variants for doctors to investigate, but also increase the number of patients that are properly diagnosed.

These potentially game-changing technologies, developed by Peter Rogan, PhD, students and his collaborators from Western's Schulich School of Medicine & Dentistry, reveal gene variants that were missed by conventional genetic testing.

Their method, described in BMC Medical Genomics, was first applied to 102 individuals at risk or with a diagnosis of inherited breast cancer. The team also studied 287 women with no known mutations for an article published in Human Mutation.

Rogan, Canada Research Chair in Genome Bioinformatics, says that 16 to 20 per cent of women in southwestern Ontario, who have their BRCA genes tested for breast and/or ovarian cancer risk, carry disease-causing gene variants that are well-understood by clinicians and genetic counselors. If a patient tests positive for an abnormal BRCA1 or BRCA2 gene and have never had breast cancer, there is a much higher-than-average risk of developing the deadly disease.

Read more: New gene testing method can identify mutations, prioritize variants in breast and ovarian cancer genes

Source: azonano

Novel Biomarker Predicts Breast Cancer Risk in Asymptomatic Women

A biomarker has been identified that may allow clinicians to predict the risk of an asymptomatic woman eventually developing breast cancer.

To identify this disease indicator, investigators at Harvard Medical School studied the association between breast cancer risk and the frequency of mammary epithelial cells expressing the proteins p27 (Cyclin-dependent kinase inhibitor 1B), estrogen receptor (ER), and Ki67 (Marker of proliferation Ki-67) in normal breast tissue from 302 women (69 breast cancer cases, 233 controls) who had been initially diagnosed with benign breast disease.

Immunofluorescence assays for p27, ER, and Ki67 were performed on tissue microarrays constructed from benign biopsies containing normal mammary epithelium and scored by computational image analysis.

Read more: Novel Biomarker Predicts Breast Cancer Risk in Asymptomatic Women

Source: gettyimages